Velabs Therapeutics
Velabs Therapeutics is a pioneer in microfluidics-based technologies for functional screening of antibodies.
Velabs Therapeutics is active in the biotechnology, health care, medical space based in European Union (EU), Europe, Middle East, and Africa (EMEA), founded in 2017.
Velabs Therapeutics is positioned in biotechnology, health care, medical, a segment that rewards a clear, focused offering.
Its base of operations is European Union (EU), Europe, Middle East, and Africa (EMEA).
Its current recorded stage is Series_B.
Recorded headcount: c_00011_00050 employees.
Total disclosed funding stands at about $3M.
| Sector | Biotechnology, Health Care, Medical |
|---|---|
| Headquarters | European Union (EU), Europe, Middle East, and Africa (EMEA) |
| Founded | 2017 |
| Employees | c_00011_00050 |
| Stage | series_b |
| Total funding | $3,000,000 |
Website: veraxa.de
Contact details and direct channels are available to signed-in members.
Create a free account
Create a free account